Article
Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
Antiviral therapy - 1 Jan 2015
Lisboa-Neto Gaspar, Noble Caroline F, Pinho João R Rebello, Malta Fernanda M, Gomes-Gouvêa Michele S, Alvarado-Mora Mónica V, da Silva Mariliza H, Leite Andrea G B, Piccoli Leonora Z, Rodrigues Flaviane K, Carrilho Flair J, Mendes-Correa Maria C
Abstract excerpt
BACKGROUND: HCV has a high replication rate and a lack of proofreading activity, leading to a greatly diverse viral population. This diversity may lead to emergence of resistant strains in direct-acting antiviral therapy. The frequency of naturally occurring HCV protease inhibitor (PI) mutations has been addressed in many countries, but there are few data on the prevalence of these mutations in Brazilian...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.